Approval Alert | Toripalimab for Recurrent/Metastatic Nasopharyngeal Carcinoma

Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.

Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.

Data from the phase 3 JUPITER-02 study and phase 2 POLARIS-02 study support the FDA approval of toripalimab-tpzi alone and in combination with gemcitabine and cisplatin in nasopharyngeal carcinoma.